BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 38826126)

  • 1. Real-world study on the characteristics, post-nephrectomy journey, and outcomes of patients with early-stage renal cell carcinoma based on risk groups.
    Karam JA; Bhattacharya R; Ogbomo A; Gautam S; Yu R; Sundaram M; Imai K; Chhabra J; Haas NB
    Cancer Med; 2024 Jun; 13(11):e7247. PubMed ID: 38826126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Referral and adjuvant treatment patterns after nephrectomy in high-risk locoregional renal cell carcinoma.
    Dzimitrowicz H; Esterberg E; Miles L; Zanotti G; Borham A; Harrison MR
    Cancer Med; 2021 Dec; 10(24):8891-8898. PubMed ID: 34751002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isolated loco-regional recurrence after radical nephrectomy for renal cell carcinoma: a study of 22 patients.
    Fayek IS; Habashy HF; Habashy NF
    J Egypt Natl Canc Inst; 2014 Sep; 26(3):161-6. PubMed ID: 25150131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal cell carcinoma recurrence after nephrectomy for localized disease: predicting survival from time of recurrence.
    Eggener SE; Yossepowitch O; Pettus JA; Snyder ME; Motzer RJ; Russo P
    J Clin Oncol; 2006 Jul; 24(19):3101-6. PubMed ID: 16809736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and economic burdens of recurrence following nephrectomy for intermediate high- or high-risk renal cell carcinoma: A retrospective analysis of Surveillance, Epidemiology, and End Results-Medicare data.
    Sundaram M; Song Y; Rogerio JW; Zhang S; Bhattacharya R; Adejoro O; Carley C; Zhu JJ; Signorovitch J; Haas NB
    J Manag Care Spec Pharm; 2022 Oct; 28(10):1149-1160. PubMed ID: 36048895
    [No Abstract]   [Full Text] [Related]  

  • 6. Survival outcomes and practice trends for off-label use of adjuvant targeted therapy in high-risk locoregional renal cell carcinoma.
    Chakiryan NH; Acevedo AM; Garzotto MA; Chen Y; Liu JJ; Isharwal S; Amling CL; Kopp RP
    Urol Oncol; 2020 Jun; 38(6):604.e1-604.e7. PubMed ID: 32241693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome of isolated renal cell carcinoma fossa recurrence after nephrectomy.
    Itano NB; Blute ML; Spotts B; Zincke H
    J Urol; 2000 Aug; 164(2):322-5. PubMed ID: 10893575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncologic outcomes of patients with positive surgical margin after partial nephrectomy: a 25-year single institution experience.
    Petros FG; Metcalfe MJ; Yu KJ; Keskin SK; Fellman BM; Chang CM; Gu C; Tamboli P; Matin SF; Karam JA; Wood CG
    World J Urol; 2018 Jul; 36(7):1093-1101. PubMed ID: 29488096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histologic subtype needs to be considered after partial nephrectomy in patients with pathologic T1a renal cell carcinoma: papillary vs. clear cell renal cell carcinoma.
    Yoo S; You D; Jeong IG; Song C; Hong B; Hong JH; Ahn H; Kim CS
    J Cancer Res Clin Oncol; 2017 Sep; 143(9):1845-1851. PubMed ID: 28451753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Partial Nephrectomy is Associated with Higher Risk of Relapse Compared with Radical Nephrectomy for Clinical Stage T1 Renal Cell Carcinoma Pathologically Up Staged to T3a.
    Shah PH; Moreira DM; Patel VR; Gaunay G; George AK; Alom M; Kozel Z; Yaskiv O; Hall SJ; Schwartz MJ; Vira MA; Richstone L; Kavoussi LR
    J Urol; 2017 Aug; 198(2):289-296. PubMed ID: 28274620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system.
    Lam JS; Shvarts O; Leppert JT; Pantuck AJ; Figlin RA; Belldegrun AS
    J Urol; 2005 Aug; 174(2):466-72; discussion 472; quiz 801. PubMed ID: 16006866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histological subtype of renal cell carcinoma significantly affects survival in the era of partial nephrectomy.
    Nguyen DP; Vertosick EA; Corradi RB; Vilaseca A; Benfante NE; Touijer KA; Sjoberg DD; Russo P
    Urol Oncol; 2016 Jun; 34(6):259.e1-8. PubMed ID: 26947350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Features associated with recurrence beyond 5 years after nephrectomy and nephron-sparing surgery for renal cell carcinoma: development and internal validation of a risk model (PRELANE score) to predict late recurrence based on a large multicenter database (CORONA/SATURN Project).
    Brookman-May S; May M; Shariat SF; Xylinas E; Stief C; Zigeuner R; Chromecki T; Burger M; Wieland WF; Cindolo L; Schips L; De Cobelli O; Rocco B; De Nunzio C; Feciche B; Truss M; Gilfrich C; Pahernik S; Hohenfellner M; Zastrow S; Wirth MP; Novara G; Carini M; Minervini A; Simeone C; Antonelli A; Mirone V; Longo N; Simonato A; Carmignani G; Ficarra V;
    Eur Urol; 2013 Sep; 64(3):472-7. PubMed ID: 22748912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of a Postoperative Nomogram Predicting Recurrence in Patients with Conventional Clear Cell Renal Cell Carcinoma.
    Lee BH; Feifer A; Feuerstein MA; Benfante NE; Kou L; Yu C; Kattan MW; Russo P
    Eur Urol Focus; 2018 Jan; 4(1):100-105. PubMed ID: 28753780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Local Recurrence Following Resection of Intermediate-High Risk Nonmetastatic Renal Cell Carcinoma: An Anatomical Classification and Analysis of the ASSURE (ECOG-ACRIN E2805) Adjuvant Trial.
    Lee Z; Jegede OA; Haas NB; Pins MR; Messing EM; Manola J; Wood CG; Kane CJ; Jewett MAS; Flaherty KT; Dutcher JP; DiPaola RS; Uzzo RG
    J Urol; 2020 Apr; 203(4):684-689. PubMed ID: 31596672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Percutaneous Radiofrequency Ablation Versus Robotic-Assisted Partial Nephrectomy for the Treatment of Small Renal Cell Carcinoma.
    Pantelidou M; Challacombe B; McGrath A; Brown M; Ilyas S; Katsanos K; Adam A
    Cardiovasc Intervent Radiol; 2016 Nov; 39(11):1595-1603. PubMed ID: 27435582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Laparoscopic radical versus partial nephrectomy for tumors >4 cm: intermediate-term oncologic and functional outcomes.
    Simmons MN; Weight CJ; Gill IS
    Urology; 2009 May; 73(5):1077-82. PubMed ID: 19394509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiofrequency ablation versus partial nephrectomy in patients with solitary clinical T1a renal cell carcinoma: comparable oncologic outcomes at a minimum of 5 years of follow-up.
    Olweny EO; Park SK; Tan YK; Best SL; Trimmer C; Cadeddu JA
    Eur Urol; 2012 Jun; 61(6):1156-61. PubMed ID: 22257424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy: a multicenter European study.
    Cindolo L; Patard JJ; Chiodini P; Schips L; Ficarra V; Tostain J; de La Taille A; Altieri V; Lobel B; Zigeuner RE; Artibani W; Guillé F; Abbou CC; Salzano L; Gallo C
    Cancer; 2005 Oct; 104(7):1362-71. PubMed ID: 16116599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term oncologic outcomes after radiofrequency ablation for T1 renal cell carcinoma.
    Psutka SP; Feldman AS; McDougal WS; McGovern FJ; Mueller P; Gervais DA
    Eur Urol; 2013 Mar; 63(3):486-92. PubMed ID: 22959191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.